Abstract The World Health Organization (WHO) emphasizes that tuberculosis preventive treatment is a key measure for ending the tuberculosis epidemic. In 2023, Huzhou City initiated the construction of Zero Tuberculosis City based on the pilot program of Zero Tuberculosis Communities in Zhejiang Province, and established a three-level tuberculosis preventive treatment system for latent tuberculosis infection (LTBI) at the municipal, county (district), and township (subdistrict) levels. Strategies including formulating standards and norms, promoting preventive treatment clinics at all levels, improving staffing and clarifying work responsibilities were implemented to strengthen active intervention and management of LTBI and improve the standardization of preventive treatment. From 2023 to 2024, a total of 27 535 individuals tested positive for Mycobacterium tuberculosis (MTB) in Huzhou City. The acceptance rate of preventive treatment was 34.82%, and the completion rate was 57.89%. During follow-up, the incidence density of active pulmonary tuberculosis among MTB-positive individuals who did not receive preventive treatment was 393.83/105 person-years, while that among individuals who received preventive treatment but interrupted treatment was 293.83/105 person-years, and that among individuals who received and completed preventive treatment was 46.08/105 person-years. Practices have shown that the LTBI preventive treatment system constructed in Huzhou City features strong accessibility and high operability, which has effectively expanded the coverage of interventions for high-risk groups, significantly reduced the risk of active pulmonary tuberculosis among MTB-positive individuals, and provided a replicable and promotable practical paradigm for LTBI prevention and control nationwide. In the future, Huzhou City will continue to rely on the primary medical and health network to optimize the whole-process standardized management of LTBI, leverage smart prevention and control technologies, optimize diagnosis and treatment services and cross-regional linkage mechanisms, continuously consolidate the achievements of the Zero Tuberculosis City initiative, steadily reduce the regional tuberculosis epidemic, and contribute to the achievement of the strategic goal of ending the tuberculosis epidemic.

Objective To explore the key genes of cardiac aging by bioinformatic analysis,and conduce to prevent and treat cardio-vascular diseases in the elderly.Methods The gene expression of GSE8146 was downloaded from the Gene Expression Omnibus(GEO)database."R"software was used to screen out differentially expressed genes in the hearts of young and old mice,and DAVID online anal-ysis tool was used for Gene Ontology(GO)function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG)signa-ling pathway enrichment analysis of differentially expressed genes.Hub genes were obtained by protein-protein interaction(PPI)analy-sis based on the STRING online database.Results A total of 55 differentially expressed genes were screened,including 22 up-regula-ted genes and 33down-regulated genes.The differentially expressed genes were significantly enriched in lipid metabolism,fatty acid me-tabolism and other processes,mainly involvded in peroxisome proliferators-activated receptor(PPAR)signaling pathway and Adenosine 5′-monophosphate(AMP)-activated protein kinase(AMPK)signaling pathway.The hub genes such as Fasn,Pck1,Adipoq,Cpt1a,Pdk4,Pnpla2,Slc27a1,Hmgcs2,Cidec,Ucp3 were screened out.Conclusion Cardiac aging may be related to the disorder of cellular energy metabolism,and hub genes such as Fasn,Pck1,Adipoq,Cpt1a,Pdk4,Pnpla2,Slc27a1,Hmgcs2,Ucp3,PPAR signaling path-way and AMPK signaling pathway may play an important role in the development of cardiac aging.

Objective To prepare gemcitabine hydrochloride thermosensitive gel injection and to stablish the determina‐tion methods of its contents .Methods Gemcitabine hydrochloride thermosensitive gel injection was prepared using PLGA‐PEG‐PLGA as thermosensitive viecle .The contents of gemcitabine hydrochloride were determined by HPLC .Results The formulation contained 40 mg/ml gemcitabine and 20% (wt) PLGA‐PEG‐PLGA with phase‐transition temperature of (37 ± 0 .15) ℃ ,showing the best viscosity around human body temperature .Gemcitabine hydrochloride presented a good linearity in the range of 5‐500 μg/ml(r=0 .999 8) ,which had good precision and reproducibility .The recovery rate of low ,middle and high concentrations of gemcitabine hydrochloride were (99 .5 ± 3 .2)% ,(100 .4 ± 2 .4)% ,(102 .1 ± 2 .4)% ,n=3 ,respectively . The average contents of gemcitabine hydrochloride in three batches of sample were (101 .87 ± 2 .95)% ,(99 .4 ± 2 .73)% , (98 .98 ± 0 .71)% ,n=3 ,respectively .Conclusion The quality of gemcitabine hydrochloride thermosensitive gel injection with PLGA‐PEG‐PLGA as matrix could be controlled .It is a promising new drug for pancreatic cancer .

Objective:To compare the therapeutic and adverse effects of concurrent raltitrexed plus oxaliplatin and radiotherapy with those of PF synchronous radiotherapy in the treatment of advanced esophageal cancer. Methods:A total of 84 pathologically con-firmed patients with advanced esophageal carcinoma were randomly distributed to the concurrent raltitrexed plus oxaliplatin and ra-diotherapy group (experimental group, n=40) and to the PF synchronous radiotherapy group (control group, n=44). All patients were treated with 3DCRT at a total dose of 60 Gy/30f. The chemotherapy in the experimental group consists of raltitrexed at 2.5 mg/m2, d1, plus oxaliplatin at 130 mg/m2, d2. The chemotherapy of the control group consists of DDP at 25 mg/m2, Dd1-3, plus 5-FU 500 mg/m2, d1-5. Two cycles of concurrent chemotherapy were administered during radiotherapy on d1 and d29. The comparison results were used to estimate the therapeutic and adverse effects of the two groups. Results:The rerponse rate, complete response, and one-year overall survival rate of the experimental group were higher than those of the control group [(87.50%vs. 79.54%, P=0.3293), (32.50%vs. 18.18%, P=0.13), and (82.50%vs. 79.50%, P=0.701)], but the difference was not statistically significant. The incidence rates of nau-sea and vomiting, appetite degression, leucopenia, radiation-induced esophagitis, and cardiotoxicity were significantly lower (P<0.05) in the experimental group than in the control group. Other adverse effects of the two groups were similar (P>0.05). Conclusion:Simi-lar to PF chemotherapy and radiotherapy, the concurrent raltitrexed plus oxaliplatin and radiotherapy achieved a similar short-term therapeutic effect but lower adverse effects on patients with esophageal cancer.

Objective To evaluate the role of transesophageal echocardiography (TEE) in perioperative period of pediatric patients with congenital heart disease (CHD).Methods From July 2011 to December 2012,TEE was used in 393 pediatric patients(≤ 14 years) with congenital heart disease in perioperative period.We make a retrospective review with the clinical data of these cases.Results Operative schemes or therapeutic schedules of 60 patients(15.3％) were altered according to TEE.By preoperative TEE,the diagnosis of transthoracic echocardiography (TTE) of 4 cases(1.0％) were amended,4 cases (1.0％) were complemented,and 4 cases (1.0％) got the auxiliary diagnosis,among which operative schemes of 11 cases (2.8％)were altered.During the operate,29 cases(7.4％) found residual problems,11 cases(2.8％) got the auxiliary diagnosis.By postoperative TEE,7 cases(1.8％) found residual problems,1 case(0.3％) got the auxiliary diagnosis.Complications occurred in 9 cases(2.3％) of the 393 patients.Oral and pharyngeal mucous membrane bleeding occurred in 7 cases (1.8％),inadvertent tracheal extubation in 2 cases(0.5％).Conclusion TEE plays an important role in confirming preoperative diagnoses,formulating surgical plans,evaluating immediate operative results,identifying patients with residual defects and guiding the therapeutic schedule in perioperative period of pediatric patients with congenital heart disease.